{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:23:38Z","timestamp":1783488218139,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ophtha.2009.05.029","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T06:58:00Z","timestamp":1255071480000},"page":"133-139.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy"],"prefix":"10.1016","volume":"117","author":[{"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K.L.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoo F.","family":"Afifiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene Chokron","family":"Garneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine H.","family":"Darwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2009.05.029_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2265.2008.03338.x","article-title":"The incidence of autoimmune thyroid disease: a systematic review of the literature","volume":"69","author":"McGrogan","year":"2008","journal-title":"Clin Endocrin (Oxf)"},{"key":"10.1016\/j.ophtha.2009.05.029_bib3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2009.05.029_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/thy.2007.0404","article-title":"Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy","volume":"18","author":"Smith","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2009.05.029_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2249.2006.03316.x","article-title":"Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes","volume":"148","author":"Douglas","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib6","first-page":"776","article-title":"Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy","volume":"85","author":"Aniszewski","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2009.05.029_bib7","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/35100573","article-title":"From T to B and back again: positive feedback in systemic autoimmune disease","volume":"1","author":"Shlomchik","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/IOP.0b013e318179f8a5","article-title":"Novel immunomodulating agents for Graves' orbitopathy","volume":"24","author":"Bartalena","year":"2008","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2009.05.029_bib10","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2009.05.029_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/WNO.0b013e31814a5ef8","article-title":"Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease","volume":"27","author":"Zoumalan","year":"2007","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2009.05.029_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1517\/14712598.7.7.1061","article-title":"B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves' ophthalmopathy the latest addition to an expanding family","volume":"7","author":"Nielsen","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ophtha.2009.05.029_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2009.05.029_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/eje.1.02140","article-title":"The rationale for B lymphocyte depletion in Graves' disease: monoclonal anti-CD20 antibody therapy as a novel treatment option","volume":"154","author":"El Fassi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib17","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2009.05.029_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves' disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib20","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1210\/jc.2007-0463","article-title":"B cell depletion in Graves' disease: the right answer to the wrong question?","volume":"92","author":"Smith","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2009.05.029_bib21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0002-9394(14)72787-4","article-title":"Diagnostic criteria for Graves' ophthalmopathy","volume":"119","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3928\/15428877-20060701-04","article-title":"Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy","volume":"37","author":"Ben Simon","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2009.05.029_bib24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ajo.2006.01.066","article-title":"Medial wall decompression for optic neuropathy but lateral wall decompression with fat removal for non vision-threatening indications","volume":"141","author":"McCann","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12016-007-8024-3","article-title":"Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy","volume":"34","author":"Bonara","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-065X.2008.00637.x","article-title":"Human regulatory T cells: role in autoimmune disease and therapeutic opportunities","volume":"223","author":"Brusko","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ophtha.2009.05.029_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jbspin.2008.08.002","article-title":"Regulatory T cells (Treg) in rheumatoid arthritis","volume":"76","author":"Boissier","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ophtha.2009.05.029_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-008-0719-0","article-title":"NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis","volume":"29","author":"Reis","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ophtha.2009.05.029_bib29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/TP.0b013e31818f3d2a","article-title":"Diagnostic value of regulatory T cells: a new facet of a much studied cell population","volume":"86","author":"Brown","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.ophtha.2009.05.029_bib30","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.23715","article-title":"Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy","volume":"59","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2009.05.029_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clim.2008.09.007","article-title":"Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies","volume":"130","author":"El Fassi","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/eji.200737557","article-title":"Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab","volume":"38","author":"Ferraro","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of rituximab's immunomodulatory synovial effects (ARISE trial)","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2009.05.029_bib35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ophtha.2009.05.029_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.semarthrit.2008.01.001","article-title":"Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab","volume":"38","author":"Fleischmann","year":"2009","journal-title":"Semin Arthritis Rheum"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164200900548X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164200900548X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:57:48Z","timestamp":1758981468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164200900548X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S016164200900548X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.029","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}